Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: Relationship to adherence to treatment

Multiple Sclerosis

Volumn 2, Issue 5, 1996, Pages 222-226

  Mohr, D C ^a,b,e   Goodkin, D E ^a   Likosky, W ^c   Gatto, N ^a   Neilley, L K ^a   Griffin, C ^c   Stiebling, B ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PALO ALTO UNIVERSITY   (United States)

^c KAISER PERMANENTE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adherence; Compliance; Interferon beta 1 b; Multiple sclerosis; Side effects

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERFERON BETA SERINE; INTERFERON BETA-1B;

ARTICLE; ATTITUDE TO HEALTH; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PATIENT; PATIENT COMPLIANCE; PATIENT EDUCATION;

ADJUVANTS, IMMUNOLOGIC; ATTITUDE TO HEALTH; FEMALE; HUMANS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PATIENT DROPOUTS; PATIENT EDUCATION;

EID: 0030332317     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245859600200502     Document Type: Article

References (11)

1. Goodkin DE. (1994) Drug profile: Interferon beta-1b. Lancet 344: 57-1060.
2. INFB. MS Study Group. (1993) Interferon beta-1-b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655-661.
3. INFB. MS Study Group. (1993) Interferon beta-1-b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter randomized double-blind placebo-controlled trial. Neurology 43: 662-667.
4. Neilley LK et al. (1995) Side effect profile of interferon beta 1-b (Betaseron). Neurology 45: A437.
5. Goodkin DE. (1996) Interferon beta treatment for multiple sclerosis: Persisting question. Multiple Sclerosis 1: 321-324.
6. O'Brien MK, Petrie K, Raeburn J. (1992) Adherence to medication regimens: Updating a complex medical issue. Medical Care Review 49: 435-445.
7. Becker MH et al. (1979) Patient perceptions and compliance: Recent studies of the health belief model. Compliance in Health Care. Edited by RB Haynes, DW Taylor, DL Sachett. Baltimore MD: Johns Hopkins University Press.
8. Poser CM et al. (1983) New diagnostic criteria for multiple sclerosis. Ann Neurol 13: 227-231.
9. Mohr DC et al. (1995) Expectations of multiple sclerosis patients initiating Betaseron therapy [abstract]. Neurology 45 (suppl 4): 197.
10. Jacobs LD et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Annals of Neurology, in press.
11. Johnson KP et al. (1995) Copolymer-1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III, multicenter, double-blind, placebo-controlled trial. Neurology 45: 1268-1276.